Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing

Alnylam shares fell sharply after the company cut full-year TTR sales guidance by $200 million, citing a normalization of pent-up demand for Amvuttra in the ATTR-CM market. However, the article highlights that Amvuttra revenue more than doubled year over year to $1.01 billion in Q2 (first quarter above $1B) and management now targets at least 25% total revenue CAGR through 2030. Competitive pressure was also framed as improving for Alnylam, with BridgeBio’s Attruby sales tripling to $222.4 million in Q2 while AstraZeneca/Ionis’ eplontersen failed a Phase 3 primary endpoint. Despite the sell-off, the author argues the decline is overdone and cites a low PEG ratio of 0.41 as valuation support.

Analysis

Alnylam’s selloff looks more like a market re-rating of the launch curve than a broken franchise. In biotech, the first derivative matters more than the absolute level: a >$1B quarter with still-robust growth can coexist with a lowered guide, and that usually means the multiple compresses before the earnings power does. The near-term winner is BridgeBio, because commercial momentum plus visible share gains tends to attract incremental capital in a category the market wants to believe is winner-take-most.

The bigger second-order effect is that the ATTR market is not a single-drug story anymore; it is becoming a share battle with payer friction and physician inertia. That favors the company with the cleanest durability narrative, but it also means ALNY can recover if subsequent quarters prove the current deceleration is simply launch normalization rather than competitive leakage. The eplontersen setback helps ALNY sentimentally, but the real read-through is to Ionis/AZN: it raises the bar for every next-gen RNA agent and can keep capital flowing toward the incumbent with approved scale.

The main risk is not one bad quarter, it is a second and third confirmation that growth is slowing faster than management now models; that would force the market to mark ALNY from growth biotech to mature specialty pharma, a materially lower multiple. The 1-3 month catalyst path is the next couple of prints and any commentary on new patient starts, switching, and gross-to-net pressure; the 6-18 month catalyst is nucresiran, which is the only thing that can reset the long-duration growth debate. Contrarian take: consensus may be over-discounting the guidance cut but underpricing how much of the valuation still depends on ALNY proving it can defend leadership after the launch honeymoon ends.

Key Decisions for Investors

• Add ALNY on weakness only as a phased position, not a chase: best entry is after the next earnings print confirms stabilization in TTR growth; upside is a multiple re-rate if growth re-accelerates, downside is another guide cut that would likely extend the de-rating.
• Pair trade: long ALNY / short IONS for a 3-6 month window. Thesis: ALNY has an approved, scaled franchise and cleaner near-term cash flow visibility, while IONS carries more residual clinical overhang after the eplontersen failure. Stop if IONS wins back credibility with unexpectedly clean ATTR-CM updates.
• Relative-value hedge: long PFE vs short BBIO if you think the market is overpaying for near-term ATTR share momentum. PFE’s patent protection makes its cash flows less fragile, while BBIO’s sales momentum is the more execution-sensitive leg if payer/reimbursement friction rises.
• Set a watch item on ALNY for the next two quarters: if TTR guidance is cut again or Amvuttra growth drops meaningfully below the current high-growth profile, treat that as confirmation the franchise is maturing faster than expected and reduce exposure.